Thanks to your incredibly generous support, Chris O’Brien Lifehouse recently took delivery of the Elekta Flexitron High Dose Brachytherapy Unit.
The urgently needed funds were raised through grants and donations given in response to our appeal.
The Elekta Flexitron High Dose Brachytherapy Unit is essential in the treatment of prostate and gynaecological cancers, providing 3D imaging for accurate and targeted delivery of radiation directly to the cancerous tissue.
Professor Chris Milross, Director of Radiation Oncology at Lifehouse, both pleased and humbled by the philanthropic support, said, “It is wonderful to have received such generous donations and grants to help us meet our critical medical equipment needs.”
In addition to the $115,000 contribution from the Royal Price Alfred Hospital, the donations from our supporters make a real difference in our work. This will ensure that we can deliver the best possible treatment using the most advanced equipment available. Everyone who has donated is making a real difference to our work.
Prostate cancer is the most commonly diagnosed cancer in Australia, while gynaecological cancers are the third most commonly diagnosed cancers among women. Brachytherapy is a crucial element in the treatment of both these cancers.
In fact, cervical cancer patients who are treated with brachytherapy in conjunction with external radiation therapy have an improved survival rate of 50% compared with patients receiving external radiation therapy alone.
The Lifehouse team would like to sincerely thank everyone who donated so generously. We really would not have been able to purchase this major piece of equipment without you!